Biopharma financing remains active, with total funding through early June reported at $49.46 billion, more than doubling the same period in 2025. The data point to a stronger capital appetite, driven by ongoing deal activity and continued investor interest even as clinical risk remains high. In parallel, Hemab surged 89% on its debut, reflecting sustained interest in new listings during May. The financing totals indicate public and private rounds remained robust, helping offset earlier contraction years. For portfolio decision-making, the signal is that capital is available for both platform bets and late-stage clinical programs, but investors are still reacting sharply to safety and regulatory outcomes as seen in multiple late-stage readouts.